Study to evaluate efficacy, safety, tolerability and pharmacokinetics of AZD1386 in patients with peripheral neuropathic pain - AVANT
Study identifier:D5090C00018
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Terminated/Withdrawn
Official Title
A Phase IIa randomised, double-blind, placebo controlled, parallel group, multicentre study evaluating the efficacy, safety, tolerability and pharmacokinetics of AZD1386 after 3 weeks of treatment in patients with Posttraumatic Neuralgia (PTN) and Postherpetic Neuralgia (PHN)
Medical condition
Pain, Neuropathic Pain
Phase
Phase 2
Healthy volunteers
No
Study drug
AZD1386, Placebo
Sex
All
Actual Enrollment
90
Study type
Interventional
Age
18 Years - 80 Years
Date
Study Start Date: 01 Sept 2009
Primary Completion Date: -
Estimated Study Completion Date: 01 Feb 2010
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Dec 2009 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 | Drug: AZD1386 90 mg, capsules, oral, during 3 weeks |
| Placebo Comparator: 2 | Drug: Placebo capsules, oral, during 3 weeks |
Contacts
Investigators
Principal Investigator
Richard L Leff
AstraZeneca R&D Wilmington, USA
